This paradox highlights the importance of combining Ki67 assessments with other prognostic factors, such as tumor size reduction, pathological complete response (pCR), and molecular subtypes, for a more accurate prediction of patient outcomes [11-12]. The gene discussed is MKI67; the disease is neoplasm.